Insulet (PODD) Revenue (2010 - 2026)

Insulet has reported Revenue for 17 years, with the latest figure at $761.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 33.87% year-over-year to $761.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 billion (up 31.93% YoY), and the FY2025 full-year result was $2.7 billion, up 30.73% from the prior year.
• Revenue for Q1 2026 stood at $761.7 million, down from $783.8 million in the prior quarter.
• The five-year high for Revenue was $783.8 million in Q4 2025, with the low at $247.0 million in Q1 2022.
• Historically, Revenue has averaged $499.7 million across 5 years, with a median of $488.5 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue fell 1.0% — and 2023, when it surged 44.98%.
• Insulet's Revenue stood at $369.7 million in 2022, then jumped by 37.9% to $509.8 million in 2023, then advanced by 17.2% to $597.5 million in 2024, then jumped by 31.18% to $783.8 million in 2025, then slipped by 2.82% to $761.7 million in 2026.
• The last three Revenue figures came in at $761.7 million (Q1 2026), $783.8 million (Q4 2025), and $706.3 million (Q3 2025), per Business Quant data.